CRL Forensic analysis

Trading Setup & Entry Strategy

Charles River Laboratories (CRL) is currently in a BEARISH_DOWNTREND, with the price trading significantly below the 50-day ($168.04) and 200-day ($175.92) SMAs. Despite oversold conditions (RSI 35.83), we are not catching a falling knife. We are targeting a potential bottoming process near the lower Bollinger Band support.

• >Entry Zone: $145.00 - $148.00. Wait for a stabilization signal (e.g., a green candle closing above $148.00) on the daily chart before deploying the first 30%.
• >Stop Loss: $138.50 (Hard stop below recent support shelf).
• >Position Sizing: 3% of portfolio.
• >Take Profit: Tiered exit at $165.00 (10-day SMA) and $172.00 (near 200-day SMA).
• >Risk/Reward: ~1:2.5.

Executive Summary

CRL is undergoing a major portfolio restructuring, divesting underperforming CDMO/Cell solutions to improve margins. While the Q1 report shows a net loss of $14.8M and significant headwinds in the DSA segment, the stock's recent 16.75% decline over 20 days suggests the market has front-run the negative guidance. We are HOLD/WAITING for a technical reversal.

Recent Material Events (8-K Analysis)

• >May 2026: Completed the sale of CDMO/Cell Solutions to GI Partners. This is a "clean-up" divestiture intended to focus on higher-margin core segments but resulted in a $118.0M pre-tax loss in Q1.
• >Feb 2026: Announced divestiture of European Discovery Services businesses. Strategic focus is shifting to NHP (Non-human primate) supply chain integration.

Financial Health

• >Revenue Quality: Total Revenue grew slightly to $995.8M vs $984.2M YOY, but operating income remains volatile.
• [CRIT]Forensic Flags: High Restructuring Costs ($31.6M in Q1). Goodwill Impairments and significant legal contingencies related to NHP importation practices.
• >Debt: Long-term debt increased to $2.66B, reflecting financing for the $507.3M Cambodian NHP acquisition.

Valuation & Technical Reconciliation

• >Reverse DCF: The market is currently pricing in stagnant growth or a contraction, given the steep discount to long-term averages.
• >Technical Analysis: The stock is in a confirmed BEARISH_DOWNTREND. With RSI at 35.83, the stock is approaching oversold territory, but MACD remains negative. We treat the recent price weakness as a potential value trap unless the $148.00 support holds.

Short-Term Trading Strategy (2-5 Days)

• >Timeframe: Swing Trade (2–5 Days).
• >Scaling Strategy: Enter 30% at $148.00; add 40% only on a successful retest of the $145.00 floor. Take profit at $158.00.
• >Catalyst: Monitoring any further news on NHP regulatory resolution.

One-Liner Thesis

CRL is a high-conviction value candidate undergoing aggressive structural deleveraging, but it remains a 'wait-and-see' play until the technical breakdown finds a clear support floor.